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Background: Co-fact©, prothrombin complex concentrate, is used for restoring the international normalized ratio
(INR) in patients on vitamin K antagonists (VKA) presenting with acute bleeding. In this prospective cohort study,
we evaluated whether adequate INR values were reached in ED patients using the Sanquin (Federation of Dutch
Thrombosis Services) treatment protocol.
Methods: We evaluated this protocol for two target INR groups: group 1, target INR ≤ 1.5 (for life-threatening
bleeding/immediate intervention); group 2, target INR 1.6−2.1 (in cases of a minor urgent surgery or serious
overdosing of anticoagulant). We specifically wanted to identify both under- and over-treated patients. Reversing
VKA anticoagulation therapy to unnecessarily low INR values may involve thrombotic risks. Apart from this risk, the
patient is also administered an excess amount of the drug. This means unnecessary costs and may present
problems with restoring an anticoagulated state at a later time.
Results: In our cohort, the Sanquin dosing protocol was followed for 45/60 patients. It appeared that out of the
41 patients in group 1 (target INR ≤ 1.5), 35 (85%) achieved the goal INR. This occurred more often than for the
19 patients in group 2 (target INR 1.6–2.1), where only 6 (32%) achieved the goal INR. Using the protocol resulted
in a positive trend toward better INR reversal in group 1.
In group 2, no relation between using the protocol and achieving the desired INR value was detected. Physicians
ignoring the proposed dose of Co-fact© prescribed significantly less Co-fact© (even when correcting for patient
weight). It appeared that patients in group 1 had a significantly lower baseline INR than patients in group 2.
Group 2 patients, on the other hand, had a baseline INR > 7.5 in 53% of the cases.
Conclusion: In our cohort, for most patients in INR group 2 treated with Co-fact©, the achieved INR value was
outside the desired range of 1.6−2.1. The supra-therapeutic range of baseline INR in group 2 may have
contributed to the different kind of bleeding witnessed in this patient group.
Our results support the idea that treatment of patients on vitamin K antagonists with Co-fact© could benefit from
a slightly different approach, taking into account the INR value to which the patient needs to be reversed.* Correspondence: f.roodheuvel@gmail.com
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Male N 42/60 (70%)
PCC Indication (n)
Intracranial bleeding 21 (35%) 21 0
Gastrointestinal bleeding 14 (23.3%) 8 6
Pre-surgery/intervention 11 (18.3%) 6 5
Intramuscular hematoma 4 (6.7%) 0 4
Postoperative bleeding 3 (5.0%) 1 2
Post-traumatic bleeding 2 (3.3%) 2 0
Pulmonary bleeding 2 (3.3%) 1 1
Pharyngeal bleeding 1 (1.7%) 0 1
Hematuria (unstable patient) 1 (1.7%) 1 0
Bleeding with acute abdominal
aneurysm
1 (1.7%) 1 0
Mean age (years) (SD) 69 (± 12.7) 70.1 (± 12.4) 66.8 (± 13.3)
Mean estimated weight 80.5 (± 13.7) 81.5 (± 12.6) 78.2 (± 15.9)
Baseline INR 5.23 (± 2.96) 4.20 (± 2.13) 7.44 (± 3.32)
Mean PCC dose (ml)
Dosing table used 66.2 (± 22.1) 74.6 (± 22.5) 52.5 (± 12.5)
Dosing table not used 45.3 (± 19.6) 48.5 (± 19.1) 25 (± 7.1)
Combined 61.0 (± 23.2) 66.3 (± 24.6) 49.5 (± 14.7)
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Many patients admitted to the emergency department
(ED) use anticoagulants, mostly vitamin K antagonists
(VKA). Newman et al. [1] showed that the majority
of patients in the ED using VKA had a sub- or supra-
therapeutic international normalized ratio (INR). Chronic
anticoagulation is associated with an increased risk
of bleeding, which is related to the degree of anti-
coagulation, e.g., the height of the INR [2]. Patients
using VKA presenting to the ED with hemorrhage
have increased morbidity and mortality compared with pa-
tients not using VKA.
In addition to resuscitation measures, standard treat-
ment of VKA-associated bleeding includes improvement
of coagulation status. Vitamin K, fresh frozen plasma, or
prothrombin complex concentrate (PCC, Co-fact©) are
the most used treatment options in the Netherlands.
Sanquin, the Federation of Dutch Thrombosis Services
and manufacturer/supplier of Co-fact©, provides a
dosing regimen (Additional file 1) in which the pro-
posed amount of PCC to be administered is related
to the INR at presentation, the weight of the patient,
and the desired target INR. This desired target INR
depends on the indication: a target INR ≤ 2.1 is the
aim in case of a minor (urgent) surgery or serious
overdosing of anticoagulant with bleeding complica-
tions, while a target INR ≤ 1.5 is the aim for severe
bleeding complications with hemodynamic instability
or cerebral bleeding, or if acute surgical intervention
is needed [3,4].
Through regular use in our ED, we observed that
treatment with Co-fact© is not optimal in every case.
Desired INR target values are not always reached,
with patients being over-treated with PCC and thus
reaching lower INR values than necessary. There are
also patients in whom the INR stays above the desired
value. Both these outcomes may be unfavorable for
the patient. The risk of an INR value above the de-
sired target in an actively bleeding patient is evident.
On the other hand, reversing VKA anticoagulation
therapy to unnecessarily low INR values may come
with thrombotic risks. These risks may vary with each
individual patient, depending on their indication for
VKA therapy and risk stratum [5,6]. Apart from this
risk, the patient is additionally administered an excess
amount of drug that was not needed. This results in
unnecessary costs and may present problems with re-
storing anti-coagulated state later on.
The aim of this study was to evaluate whether adequate
INR values were reached when administering Co-fact© to
ED patients using the Sanquin treatment protocol. We
evaluated the results of this protocol in two different INR
target groups (group 1, target INR ≤ 1.5; group 2, target
INR 1.6–2.1).Methods
Patients
Sixty-two patients (female 20/male 42) admitted to
our university hospital-based ED were included in a
13-month period from July 2010 to August 2011. Inclu-
sion criteria were: the need for acute VKA reversal and
age > 18 years. Exclusion criteria were administration
of vitamin K, FFP, or PCC prior to the ED visit. There
were no referrals from other medical institutions in our
cohort. Two patients were excluded afterwards because
of missing data such as endpoint INR values and de-
sired target INR values.
Study design
This was a prospective observational cohort study, in
which regular patient care was provided. The decision to
treat a patient with Co-fact© was made by the treating
physician; the investigator had no influence on this
process. Approval from the ethics committee was waived
since the study only observed treatment and no inter-
ventions were performed.
Physicians of included patients filled out an investiga-
tion form where patient characteristics were noted, such
as age, sex, and estimated weight. The desired target
INR, the admission INR, the amount of Co-fact© adminis-
tered, time between administering Co-fact© and drawing a
Table 2 Results reaching target
INR ≤ 1.5 INR 1.6−2.1
Target INR reached/total (%) 35/41 (85%) 6/19 (32%)
Dosing table used 28/41 (68%) 17/19 (89%)
Target reached when dosing table used 26/28 (93%) 5/17 (29%)




INR ≤ 1.5 reached/total (%) 26/28 (93%) 9/13 (69%)
INR 1.6−2.1 reached/total (%) 5/17 (29%) 1/2 (50%)
Roodheuvel et al. International Journal of Emergency Medicine 2013, 6:14 Page 3 of 4
http://www.intjem.com/content/6/1/14new blood sample for INR control, and the achieved INR
value were noted. Following the protocol, Co-fact© was ad-
ministered at 2 ml/min. The control blood sample had to
be drawn 15 min after the completed administration of the
full dose.
The usage and amounts of vitamin K or fresh frozen
plasma were noted. Eventually, physicians had to explain
why they had not used the proposed dosing regimen.
In group 1 (target INR ≤ 1.5) inadequate VKA reversal
was represented by values of INR > 1.5.
In analyzing the data for target group 2 (target INR
1.6–2.1), a deliberate difference was made between
achieving an INR ≤ 2.1 or achieving an INR between
1.6 and 2.1. The reason for this was that we specific-
ally wanted to identify both under- and over-treated
patients. Over-treated patients could have been treated
with less Co-fact© than was originally administered,
while under-dosed patients should have been treated
with more. This is a different approach than the manu-
facturer of Co-fact© uses. They state that any INR ≤ 2.1 is
adequate for INR group 2 (target INR 1.6–2.1). When
taking only the acute bleeding episode into account, this
may be true. However, reversing INR to normal levels
in a patient with no life-threatening bleeding may be
unfavorable [6].Figure 1 INR reduction in two target groups (G1 = target INR ≤ 1.5, GStatistical analysis
Both baseline and endpoint data are presented as the
mean ± standard deviation. Data are presented as case
series with proportions and percentages when appropri-
ate. Due to the small sample size, no significance testing
was performed. Calculations, data storage, and statistical
analysis were performed with Microsoft Excel, SPSS ver-
sion 18, and GraphPad software.
Results
The most relevant included patient categories were
patients with intracranial bleeding, gastrointestinal bleed-
ing, or requiring an acute intervention (diagnostic or
treatment-related). There was no difference in age, weight,
measured time, or use of vitamin K between INR target
groups (Table 1). When vitamin K was administered, in
86% of the cases the dose was 10 mg. There was no differ-
ence in administration between the INR target groups and,
as expected, no relation with achieving an adequate goal
INR. When comparing estimated weight and measured
weight, the mean difference was 2.48 kg (± 6.9 kg). Sanquin
divides patients into 10-kg categories for dose calculation;
the observed weight difference had no influence on dosing
of our patients. Fresh frozen plasma (FFP) was adminis-
tered only once; no further statistical analysis on this sub-
ject was performed.
There was a great difference in both baseline INR
values and in the amount of Co-fact© administered be-
tween groups 1 and 2.
Of the 41 patients in group 1, the protocol was followed
in 28, and 26 (93%) reached their target INR (Table 2).
This was more often than for patients in group 2: of the
19 patients in this group, the protocol was followed in 17
patients, and only 5 patients (32%) reached their target
INR. Out of the 13 patients in group 1 where the proto-
col was not followed, 9 (69%) reached their target INR.
There were only two cases in group 2 where the protocol2 = target INR 1.6−2.1).
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patients did not reach the target INR range: 9 patients
had INR values ≤ 1.5 and 4 patients > 2.1.
Conclusions and discussion
In our cohort, the Sanquin dosing protocol was followed
for 45 patients and not followed for 15 patients. Patients
in group 1 (target INR ≤ 1.5) achieved the goal INR sig-
nificantly more often than patients in group 2 (Target
INR 1.6–2.1), even when the protocol was ignored.
Using the protocol resulted in a positive trend toward
better INR reversal in group 1. In group 2, no relation
between using the protocol and achieving the desired
INR value was detected. Physicians ignoring the proposed
dose of Co-fact© prescribed significantly less Co-fact©
(even when correcting for patient weight).
It appeared that patients in group 1 had a significantly
lower baseline INR than patients in group 2. Group 2
patients, on the other hand, had a baseline INR > 7.5 in
53% of the cases (Figure 1). This supra-therapeutic range
of INR may have contributed to the different kind of
bleeding witnessed in this patient group.
In our cohort, the achieved INR values were outside the
desired range of 1.6−2.1 for most patients in group 2 who
were treated with Co-fact©. Patients in group 2 by defin-
ition did not have life-threatening bleeding or bleeding re-
quiring immediate intervention. For these patients, we
propose a more conservative approach. For instance, after
administration of a fixed bolus dose, a new blood sample
for INR assessment can be drawn. When the new INR
value is known (which usually occurs within 30 min, but
can be even quicker when using point-of-care measure-
ments in the ED), patients requiring extra VKA reversal
after the first bolus can be treated accordingly. With an ini-
tially lower amount of Co-fact© administered, the percent-
age of over-treated patients can be reduced. The total delay
with this method is not more than 30 min, and overdosing
of Co-fact© can be reduced, which could reduce complica-
tions of overdosing and is cost effective.
Based on the number of patients in our cohort, it is
difficult to draw very solid conclusions. Also, the INR
target groups were not the same size, which makes com-
parison between these groups less powerful.
However, this prospective cohort study was intended
to test our hypothesis and give possible directions for fu-
ture research. The results support the idea that treat-
ment of patients on vitamin K antagonists with Co-fact©
could benefit from a slightly different approach, as sug-
gested above.
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